Heier, Jeffrey S.

Ranibizumab for Neovascular Age-Related Macular Degeneration

Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 5,886

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration

Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 3,522

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration

Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 2,485

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 1,318

Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

Schmidt-Erfurth, U., Kaiser, P. K., Korobelnik, J.-F., Brown, D. M., Chong, V., Nguyen, Q. D., Ho, A. C., Ogura, Y., Simader, C., Jaffe, G. J., et al. (2014) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 822

Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration

Chen, W., Stambolian, D., Edwards, A. O., Branham, K. E., Othman, M., Jakobsdottir, J., Tosakulwong, N., Pericak-Vance, M. A., Campochiaro, P. A., Klein, M. L., et al. (2010) · Proceedings of the National Academy of Sciences

Retinal Diseases and TreatmentsGenetic Associations and Epidemiology

Cited by 506

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 500

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion–Related Events with Brolucizumab

Monés, J., Srivastava, S. K., Jaffe, G. J., Tadayoni, R., Albini, T. A., Kaiser, P. K., Holz, F. G., Korobelnik, J.-F., Kim, I. K., Pruente, C., et al. (2021) · Ophthalmology

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 351

Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: Year 1 Results of the FOCUS Study

Heier, J. S. (2006) · Archives of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 304

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

Heier, J. S., Kherani, S., Desai, S., Dugel, P., Kaushal, S., Cheng, S. H., Delacono, C., Purvis, A., Richards, S., Le-Halpere, A., et al. (2017) · The Lancet

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 229

Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab

Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013) · British Journal of Ophthalmology

Retinal Diseases and TreatmentsRetinal and Macular Surgery

Cited by 161

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

Patel, S. S., Lally, D. R., Hsu, J., Wykoff, C. C., Eichenbaum, D., Heier, J. S., Jaffe, G. J., Westby, K., Desai, D., Zhu, L., et al. (2023) · Eye

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 147

Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study

Campochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., et al. (2024) · The Lancet

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 135

Noninfectious Inflammation After Intravitreal Injection of Aflibercept: Clinical Characteristics and Visual Outcomes

Goldberg, R. A., Shah, C. P., Wiegand, T. W., & Heier, J. S. (2014) · American Journal of Ophthalmology

Ocular Diseases and Behçet’s SyndromeRetinal Diseases and Treatments

Cited by 94

Subretinal Fluid Associated with MEK Inhibitor Use in the Treatment of Systemic Cancer

Weber, M. L., Liang, M. C., Flaherty, K. T., & Heier, J. S. (2016) · JAMA Ophthalmology

Drug-Induced Ocular ToxicityRetinal Diseases and Treatments

Cited by 86

Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration

Heier, J. S., Ho, A. C., Samuel, M. A., Chang, T., Riemann, C. D., Kitchens, J. W., Slakter, J. S., Leiderman, Y. I., Spencer, R., Williams, G. A., et al. (2020) · Ophthalmology Retina

Retinal Diseases and TreatmentsRetinal Development and Disorders

Cited by 41

Current best clinical practices—management of neovascular AMD

Brown, D., Heier, J. S., Boyer, D. S., Freund, K. B., Kaiser, P., Kim, J. E., & Sarraf, D. (2017) · Journal of VitreoRetinal Diseases

Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome

Cited by 23